ReviewFrontiers in neurology
A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026Article
- Intrathecal IgG synthesis as a biomarker for CNS involvement in anti-GQ1b antibody syndrome: a case report and hypothesis-generating treatment framework.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bickerstaff Brainstem Encephalitis (BBE) is a rare, post-infectious autoimmune disorder characterized by ophthalmoplegia, ataxia, and altered consciousness. Its significant clinical and serological overlap with Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) creates diagnostic challenges, particularly in atypical or seronegative presentations. These conditions are collectively understood as components of the anti-GQ1b antibody syndrome, a spectrum of neuro-immune disorders. Aims: This review provides a clinically focused, integrative synthesis of the anti-GQ1b antibody spectrum, with an emphasis on BBE. We aim to clarify the underlying pathophysiology, delineate the range of clinical phenotypes, provide a structured framework for diagnosis that acknowledges the limitations of ancillary testing, and summarize current evidence for therapeutic strategies. Synthesis of evidence: Pathogenesis is primarily driven by anti-GQ1b IgG antibodies, generated following infection via molecular mimicry, which trigger complement-mediated damage to ganglioside-rich neural structures. The clinical presentation ranges from purely peripheral deficits (MFS) to severe central nervous system dysfunction (BBE), with frequent BBE-GBS overlap syndromes. Diagnosis hinges on clinical recognition, supported by serology, with neuroimaging serving a crucial role in excluding mimics. Approximately one-third of clinically defined BBE cases are seronegative, suggesting alternative mechanisms. Prompt immunotherapy with intravenous immunoglobulin (IVIg) or plasma exchange is the cornerstone of management, extrapolated from GBS trials, while evidence for corticosteroids remains limited. Conclusion: A structured, spectrum-based perspective remains essential for clinicians navigating the diagnostic complexities of the anti-GQ1b antibody syndromes. This updated synthesis is intended to enhance diagnostic accuracy, guide therapeutic reasoning across the full range of phenotypes, and highlight key unresolved questions to inform a future research agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.